MA40901A - Anticorps bispécifiques anti-tnf/anti-il-3 - Google Patents

Anticorps bispécifiques anti-tnf/anti-il-3

Info

Publication number
MA40901A
MA40901A MA040901A MA40901A MA40901A MA 40901 A MA40901 A MA 40901A MA 040901 A MA040901 A MA 040901A MA 40901 A MA40901 A MA 40901A MA 40901 A MA40901 A MA 40901A
Authority
MA
Morocco
Prior art keywords
tnf
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
MA040901A
Other languages
English (en)
Inventor
Catherine B Beidler
Jr Rohn L Millican
Songqing Na
Neungseon Seo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA40901A publication Critical patent/MA40901A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA040901A 2014-11-05 2015-11-02 Anticorps bispécifiques anti-tnf/anti-il-3 MA40901A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462075571P 2014-11-05 2014-11-05

Publications (1)

Publication Number Publication Date
MA40901A true MA40901A (fr) 2017-09-12

Family

ID=54477413

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040901A MA40901A (fr) 2014-11-05 2015-11-02 Anticorps bispécifiques anti-tnf/anti-il-3

Country Status (9)

Country Link
US (1) US9718884B2 (fr)
EP (1) EP3215529A1 (fr)
JP (1) JP2017533705A (fr)
CN (1) CN108064249A (fr)
AR (1) AR102417A1 (fr)
CA (1) CA2959551C (fr)
MA (1) MA40901A (fr)
TW (1) TWI585105B (fr)
WO (1) WO2016073406A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005135A (es) * 2015-10-30 2018-06-06 Lilly Co Eli Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos.
AR111845A1 (es) * 2017-05-03 2019-08-28 Lilly Co Eli Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
CN108640997A (zh) * 2018-05-22 2018-10-12 蔡毓旻 一种双特异性抗体
KR102088789B1 (ko) * 2018-06-20 2020-03-13 인하대학교 산학협력단 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용
TWI722535B (zh) 2018-08-21 2021-03-21 美商美國禮來大藥廠 測定蛋白質或肽濃度的方法及其用途
US12098195B2 (en) 2018-11-27 2024-09-24 Innovent Biologics (Suzhou) Co., Ltd. Anti-IL-23p19 antibody and use thereof in treating diseases
MX2021014302A (es) * 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
WO2021110816A1 (fr) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRENANT DES DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT TNFα ET IL-23
JP2023525825A (ja) * 2020-05-13 2023-06-19 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ＩＬ－２３ｐ１９抗体を含む製剤、その調製方法および使用
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
CN111718414B (zh) * 2020-06-12 2021-03-02 江苏荃信生物医药有限公司 抗人白介素23单克隆抗体及其应用
AR123477A1 (es) * 2020-09-10 2022-12-07 Lilly Co Eli Formulaciones de anticuerpos terapéuticos
US20240270859A1 (en) * 2020-12-09 2024-08-15 Hk Inno.N Corporation ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFa BISPECIFIC ANTIBODY, AND USES THEREOF
CN120265663A (zh) * 2022-09-21 2025-07-04 英脉生物医药(杭州)有限公司 靶向TNFα和IL-23的抗体及其用途
WO2025024723A1 (fr) * 2023-07-26 2025-01-30 Sorriso Pharmaceuticals, Inc. Traitement par induction d'il-23 et de tnf-alpha pour des troubles auto-immuns et inflammatoires
WO2025076251A1 (fr) * 2023-10-05 2025-04-10 Sorriso Pharmaceuticals, Inc. Dosages d'inhibiteurs d'il-23 et de tnf-alpha destinés à être utilisés dans des troubles auto-immuns et inflammatoires
CN117534732B (zh) * 2023-11-03 2024-10-22 湖南中晟全肽生物科技股份有限公司 一种抑制il-12与其受体结合的多肽及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (fr) 1993-10-07 1995-04-13 The Regents Of The University Of California Anticorps bispecifiques et tetravalents, obtenus par genie genetique
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP2319870A3 (fr) 1999-03-25 2011-10-26 Abbott GmbH & Co. KG Anticorps humains qui se lient au IL-12 humain et procédé de fabrication
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
WO2004042009A2 (fr) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition de la production d'il-17
CA2506672C (fr) 2002-12-23 2012-04-17 Schering Corporation Il-23 destine au traitement des lesions cutanees
TWI439285B (zh) 2003-03-10 2014-06-01 Merck Sharp & Dohme Ｉｌ－２３激動劑及拮抗劑之用途及相關試劑
WO2006068987A2 (fr) 2004-12-20 2006-06-29 Schering Corporation Utilisations de cytokine mammalienne, reactifs associes
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2347690T3 (es) 2005-08-25 2010-11-03 Eli Lilly And Company Anticuerpos anti-il-23.
ME02705B (fr) * 2005-08-31 2017-10-20 Merck Sharp & Dohme Anticorps anti-il-23 obtenus par genie genetique
EP2116258A1 (fr) * 2005-09-01 2009-11-11 Schering Corporation Utilisation des antagonistes IL-23 et IL-17 pour traiter la maladie inflammatoire oculaire auto-immune
PT2548577T (pt) 2005-12-29 2017-05-29 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
JP2009540018A (ja) * 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
CA2672229A1 (fr) * 2006-12-14 2008-06-19 Actogenix N.V. Delivrance de molecules de liaison pour induire une immunomodulation
CN101663320A (zh) * 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
SI2274008T1 (sl) * 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
EP2331078B1 (fr) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Formulations lyophilisees d'anticorps anti-il-23p19 modifies
CA2741566A1 (fr) 2008-11-03 2010-06-03 Schering Corporation Biomarqueurs de maladie inflammatoire de l'intestin et procedes apparentes du traitement
KR20110138412A (ko) 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 항-ΤΝＦ-α 항체 및 그의 용도
WO2011017294A1 (fr) * 2009-08-07 2011-02-10 Schering Corporation Anticorps anti-rankl humain
GB201013975D0 (en) * 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
KR20130010123A (ko) * 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
EP2596022A4 (fr) 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd Anticorps spécifiques anti-hétérodimère il-23
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
HK1200321A1 (en) 2011-10-24 2015-08-07 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
US20140212425A1 (en) * 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
EP2814846B1 (fr) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
EP2855745A4 (fr) * 2012-06-01 2016-01-20 Momenta Pharmaceuticals Inc Méthodes associées à l'adalimumab
WO2014100312A1 (fr) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Biomarqueurs pour la réponse au traitement du psoriasis
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
TW201444867A (zh) 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
CN105307675A (zh) 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
UA123624C2 (uk) * 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування

Also Published As

Publication number Publication date
CA2959551A1 (fr) 2016-05-12
TWI585105B (zh) 2017-06-01
EP3215529A1 (fr) 2017-09-13
CN108064249A (zh) 2018-05-22
US20160122429A1 (en) 2016-05-05
WO2016073406A1 (fr) 2016-05-12
JP2017533705A (ja) 2017-11-16
AR102417A1 (es) 2017-03-01
US9718884B2 (en) 2017-08-01
TW201627321A (zh) 2016-08-01
CA2959551C (fr) 2018-09-11

Similar Documents

Publication Publication Date Title
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
HUE051700T2 (hu) Anti-PD-1 antitestek
FR25C1022I1 (fr) Anticorps anti-pd-1
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
EP3334824A4 (fr) Anticorps anti-pd-1
DK3332006T5 (da) Hidtil ukendte anti-PD-L1-antistoffer
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3344654T3 (da) Anti-lag-3-antistoffer
SI3354729T1 (sl) Protitelesa anti-garp
EP3532489A4 (fr) Anticorps monoclonaux neutralisants anti-tl1a
HUE047929T2 (hu) Kiméra antigén receptor
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
PT3101032T (pt) Onjugado de anticorpo anti-her2-fármaco
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3250593T3 (da) Anti-transthyretin-antistoffer
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3334457T3 (da) Humaniserede anti-CCR7-receptorantistoffer
IL256097A (en) Antibody epitope
EP3383915A4 (fr) Anticorps anti-pd-1
PL3215530T3 (pl) Ulepszone przeciwciała anty-il-6
EP3212232A4 (fr) Anticorps bispécifique tétravalent anti-tlr9
MA50222A (fr) Anticorps bispécifiques anti-pd-l1-anti-tim-3